NAUT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Nautilus Biotechnology Inc (NAUT) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company shows financial stability and has promising developments in its technology pipeline, the lack of immediate revenue growth, rising operating expenses, and neutral technical indicators suggest a wait-and-see approach is more prudent. The current pre-market price of $2.42 does not present a compelling entry point given the available data.
The MACD is positive at 0.0301, indicating a mild bullish trend, but it is contracting. RSI is neutral at 40.671, showing no clear signal. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200), but the stock is trading below the pivot level of 2.575, with key support at 2.17 and resistance at 2.98. Overall, the technical indicators are neutral to mildly bullish.
Launch of the Voyager instrument and Early Access Program for Iterative Mapping, showcasing innovation and market interest.
Financial stability with $156.1 million in cash reserves, sufficient to fund operations through
Hedge funds are significantly increasing their positions in the stock.
No material revenue expected from the Early Access Program in
Operating expenses projected to rise by 15%-20% in
Net income and EPS have declined year-over-year, indicating financial challenges.
In Q4 2025, the company reported a GAAP EPS of -$0.11, beating expectations by $0.03. However, net income dropped by 21.67% YoY, and EPS declined by 21.43% YoY. Operating expenses decreased by 23%, and cash burn was reduced to $50.2 million. The company has $156.1 million in cash reserves, sufficient to fund operations through 2027.
No recent analyst ratings or price target changes specific to NAUT were provided in the data.
